Ability of Fibrin Monomers to Predict Progressive Hemorrhagic Injury in Patients with Severe Traumatic Brain Injury.
Abbreviated Injury Scale
Adult
Blood Coagulation Disorders
/ blood
Brain Hemorrhage, Traumatic
/ blood
Brain Injuries, Traumatic
/ blood
Disease Progression
Female
Fibrin Fibrinogen Degradation Products
/ metabolism
Fibrinogen
/ metabolism
Glasgow Coma Scale
Glasgow Outcome Scale
Hospital Mortality
Humans
International Normalized Ratio
Intracranial Hemorrhages
/ blood
Male
Middle Aged
Neurosurgical Procedures
/ statistics & numerical data
Partial Thromboplastin Time
Platelet Count
Prospective Studies
Prothrombin Time
Risk Assessment
Young Adult
Fibrin monomers
Glasgow Outcome Scale
Progressive hemorrhagic injury
Severe traumatic brain injury
Trauma-induced coagulopathy
Journal
Neurocritical care
ISSN: 1556-0961
Titre abrégé: Neurocrit Care
Pays: United States
ID NLM: 101156086
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
5
12
2019
medline:
17
8
2021
entrez:
5
12
2019
Statut:
ppublish
Résumé
Progressive hemorrhagic injury (PHI) is common in patients with severe traumatic brain injury (TBI) and is associated with poor outcomes. TBI-associated coagulopathy is frequent and has been described as risk factor for PHI. This coagulopathy is a dynamic process involving hypercoagulable and hypocoagulable states either one after the other either concomitant. Fibrin monomers (FMs) are a direct marker of thrombin action and thus reflect coagulation activation. This study sought to determine the ability of FM to predict PHI after severe TBI. We conducted a prospective, observational study including all severe TBI patients admitted in the trauma center. Between September 2011 and September 2016, we enrolled patients with severe TBI into the derivation cohort. Between October 2016 and December 2018, we recruited the validation cohort on the same basis. Study protocol included FM measurements and standard coagulation test at admission and two computed tomography (CT) scans (upon arrival and at least 6 h thereafter). A PHI was defined by an increment in size of initial lesion (25% or more) or the development of a new hemorrhage in the follow-up CT scan. Multivariate logistic regression analysis was applied to identify predictors of PHI. Overall, 106 patients were included in the derivation cohort. Fifty-four (50.9%) experienced PHI. FM values were higher in these patients (151 [136.8-151] vs. 120.5 [53.3-151], p < 0.0001). The ROC curve demonstrated that FM had a fair accuracy to predict the occurrence of PHI with an area under curve of 0.7 (95% CI [0.6-0.79]). The best threshold was determined at 131.7 μg/ml. In the validation cohort of 54 patients, this threshold had a negative predictive value of 94% (95% CI [71-100]) and a positive predictive value of 49% (95% CI [32-66]). The multivariate logistic regression analysis identified 2 parameters associated with PHI: FM ≥ 131.7 (OR 6.8; 95% CI [2.8-18.1]) and Marshall category (OR 1.7; 95% CI [1.3-2.2]). Coagulopathy was not associated with PHI (OR 1.3; 95% CI [0.5-3.0]). The proportion of patients with an unfavorable functional neurologic outcome at 6-months follow-up was higher in patients with positive FM: 59 (62.1%) versus 16 (29.1%), p < 0.0001. FM levels at admission had a fair accuracy to predict PHI in patients with severe TBI. FM values ≥ 131.7 μg/ml are independently associated with the occurrence of PHI.
Sections du résumé
BACKGROUND
Progressive hemorrhagic injury (PHI) is common in patients with severe traumatic brain injury (TBI) and is associated with poor outcomes. TBI-associated coagulopathy is frequent and has been described as risk factor for PHI. This coagulopathy is a dynamic process involving hypercoagulable and hypocoagulable states either one after the other either concomitant. Fibrin monomers (FMs) are a direct marker of thrombin action and thus reflect coagulation activation. This study sought to determine the ability of FM to predict PHI after severe TBI.
METHODS
We conducted a prospective, observational study including all severe TBI patients admitted in the trauma center. Between September 2011 and September 2016, we enrolled patients with severe TBI into the derivation cohort. Between October 2016 and December 2018, we recruited the validation cohort on the same basis. Study protocol included FM measurements and standard coagulation test at admission and two computed tomography (CT) scans (upon arrival and at least 6 h thereafter). A PHI was defined by an increment in size of initial lesion (25% or more) or the development of a new hemorrhage in the follow-up CT scan. Multivariate logistic regression analysis was applied to identify predictors of PHI.
RESULTS
Overall, 106 patients were included in the derivation cohort. Fifty-four (50.9%) experienced PHI. FM values were higher in these patients (151 [136.8-151] vs. 120.5 [53.3-151], p < 0.0001). The ROC curve demonstrated that FM had a fair accuracy to predict the occurrence of PHI with an area under curve of 0.7 (95% CI [0.6-0.79]). The best threshold was determined at 131.7 μg/ml. In the validation cohort of 54 patients, this threshold had a negative predictive value of 94% (95% CI [71-100]) and a positive predictive value of 49% (95% CI [32-66]). The multivariate logistic regression analysis identified 2 parameters associated with PHI: FM ≥ 131.7 (OR 6.8; 95% CI [2.8-18.1]) and Marshall category (OR 1.7; 95% CI [1.3-2.2]). Coagulopathy was not associated with PHI (OR 1.3; 95% CI [0.5-3.0]). The proportion of patients with an unfavorable functional neurologic outcome at 6-months follow-up was higher in patients with positive FM: 59 (62.1%) versus 16 (29.1%), p < 0.0001.
CONCLUSIONS
FM levels at admission had a fair accuracy to predict PHI in patients with severe TBI. FM values ≥ 131.7 μg/ml are independently associated with the occurrence of PHI.
Identifiants
pubmed: 31797276
doi: 10.1007/s12028-019-00882-6
pii: 10.1007/s12028-019-00882-6
doi:
Substances chimiques
Fibrin Fibrinogen Degradation Products
0
fibrinmonomer
0
Fibrinogen
9001-32-5
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
182-195Références
Maas AIR, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol. 2008;7(8):728–41.
pubmed: 18635021
Alali AS, Burton K, Fowler RA, Naimark DMJ, Scales DC, Mainprize TG, et al. Economic evaluations in the diagnosis and management of traumatic brain injury: a systematic review and analysis of quality. Value Health. 2015;18(5):721–34.
pubmed: 26297101
Emami P, Czorlich P, Fritzsche FS, Westphal M, Rueger JM, Lefering R, et al. Impact of Glasgow Coma Scale score and pupil parameters on mortality rate and outcome in pediatric and adult severe traumatic brain injury: a retrospective, multicenter cohort study. J Neurosurg. 2017;126(3):760–7.
pubmed: 27035177
Esnault P, Nguyen C, Bordes J, D’Aranda E, Montcriol A, Contargyris C, et al. Early-onset ventilator-associated pneumonia in patients with severe traumatic brain injury: incidence, risk factors, and consequences in cerebral oxygenation and outcome. Neurocrit Care. 2017;27(2):187–98.
pubmed: 28432539
Cepeda S, Gómez PA, Castaño-Leon AM, Martínez-Pérez R, Munarriz PM, Lagares A. Traumatic intracerebral hemorrhage: risk factors associated with progression. J Neurotrauma. 2015;32(16):1246–53.
pubmed: 25752340
Juratli TA, Zang B, Litz RJ, Sitoci K-H, Aschenbrenner U, Gottschlich B, et al. Early hemorrhagic progression of traumatic brain contusions: frequency, correlation with coagulation disorders, and patient outcome: a prospective study. J Neurotrauma. 2014;31(17):1521–7.
pubmed: 24738836
Tian H-L, Chen H, Wu B-S, Cao H-L, Xu T, Hu J, et al. D-dimer as a predictor of progressive hemorrhagic injury in patients with traumatic brain injury: analysis of 194 cases. Neurosurg Rev. 2010;33(3):359–65 (discussion 365–6).
pubmed: 20349100
Oertel M, Kelly DF, McArthur D, Boscardin WJ, Glenn TC, Lee JH, et al. Progressive hemorrhage after head trauma: predictors and consequences of the evolving injury. J Neurosurg. 2002;96(1):109–16.
pubmed: 11794591
Yuan Q, Sun Y-R, Wu X, Yu J, Li Z-Q, Du Z-Y, et al. Coagulopathy in traumatic brain injury and its correlation with progressive hemorrhagic injury: a systematic review and meta-analysis. J Neurotrauma. 2016;33(14):1279–91.
pubmed: 26850305
Stolla M, Zhang F, Meyer MR, Zhang J, Dong J-F. Current state of transfusion in traumatic brain injury and associated coagulopathy. Transfusion. 2019;59(S2):1522–8.
pubmed: 30980753
Wada H, Sakuragawa N. Are fibrin-related markers useful for the diagnosis of thrombosis? Semin Thromb Hemost. 2008;34(1):33–8.
pubmed: 18393141
Hasegawa M, Wada H, Miyazaki S, Yamaguchi T, Wakabayashi H, Fujimoto N, et al. The evaluation of fibrin-related markers for diagnosing or predicting acute or subclinical venous thromboembolism in patients undergoing major orthopedic surgery. Clin Appl Thromb Hemost. 2018;24(1):107–14.
pubmed: 28301902
Singh N, Pati HP, Tyagi S, Upadhyay AD, Saxena R. Evaluation of the diagnostic performance of fibrin monomer in comparison to D-dimer in patients with overt and nonovert disseminated intravascular coagulation. Clin Appl Thromb Hemost. 2017;23(5):460–5.
pubmed: 26574574
Hatada T, Wada H, Kawasugi K, Okamoto K, Uchiyama T, Kushimoto S, et al. Analysis of the cutoff values in fibrin-related markers for the diagnosis of overt DIC. Clin Appl Thromb Hemost. 2012;18(5):495–500.
pubmed: 22203032
Gris J-C, Cochery-Nouvellon E, Bouvier S, Jaber S, Albanese J, Constantin J-M, et al. Clinical value of automated fibrin generation markers in patients with septic shock: a SepsiCoag ancillary study. Br J Haematol. 2018;11(101):1644.
Sørensen JV, Jensen HP, Rahr HB, Borris LC, Lassen MR, Fedders O, et al. Fibrinogen and fibrin derivatives in traumatized patients: relation to injury severity and posttraumatic pulmonary dysfunction. Haemostasis. 1993;23(2):91–7.
pubmed: 8365691
Folkerson LE, Sloan D, Cotton BA, Holcomb JB, Tomasek JS, Wade CE. Predicting progressive hemorrhagic injury from isolated traumatic brain injury and coagulation. Surgery. 2015;158(3):655–61.
pubmed: 26067457
Yuan F, Ding J, Chen H, Guo Y, Wang G, Gao W-W, et al. Predicting progressive hemorrhagic injury after traumatic brain injury: derivation and validation of a risk score based on admission characteristics. J Neurotrauma. 2012;29(12):2137–42.
pubmed: 22568757
pmcid: 3419842
Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons. Guidelines for the management of severe traumatic brain injury. J Neurotrauma. 2007;24(Suppl 1):S1–106.
Wafaisade A, Lefering R, Tjardes T, Wutzler S, Simanski C, Paffrath T, et al. Acute coagulopathy in isolated blunt traumatic brain injury. Neurocrit Care. 2010;12(2):211–9.
pubmed: 19806475
Zehtabchi S, Soghoian S, Liu Y, Carmody K, Shah L, Whittaker B, et al. The association of coagulopathy and traumatic brain injury in patients with isolated head injury. Resuscitation. 2008;76(1):52–6.
pubmed: 17706857
Hamano A, Tanaka S, Takeda Y, Umeda M, Sakata Y. A novel monoclonal antibody to fibrin monomer and soluble fibrin for the detection of soluble fibrin in plasma. Clin Chim Acta. 2002;318(1–2):25–32.
pubmed: 11880109
Maegele M, Schöchl H, Menovsky T, Maréchal H, Marklund N, Buki A, et al. Coagulopathy and haemorrhagic progression in traumatic brain injury: advances in mechanisms, diagnosis, and management. Lancet Neurol. 2017;16(8):630–47.
pubmed: 28721927
de Oliveira Manoel AL, Neto AC, Veigas PV, Rizoli S. Traumatic brain injury associated coagulopathy. Neurocrit Care. 2015;22(1):34–44.
pubmed: 25052157
Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1(7905):480–4.
pubmed: 46957
Wan X, Fan T, Wang S, Zhang S, Liu S, Yang H, et al. Progressive hemorrhagic injury in patients with traumatic intracerebral hemorrhage: characteristics, risk factors and impact on management. Acta Neurochir (Wien). 2017;159(2):227–35.
Palazón-Bru A, Folgado-de la Rosa DM, Cortés-Castell E, López-Cascales MT, Gil-Guillén VF. Sample size calculation to externally validate scoring systems based on logistic regression models. PLoS ONE. 2017;12(5):e0176726.
pubmed: 28459847
pmcid: 5411086
Zhang J, He M, Song Y, Xu J. Prognostic role of D-dimer level upon admission in patients with traumatic brain injury. Medicine (Baltimore). 2018;97(31):e11774.
Gando S, Hayakawa M. Pathophysiology of trauma-induced coagulopathy and management of critical bleeding requiring massive transfusion. Semin Thromb Hemost. 2016;42(2):155–65.
pubmed: 26716498
Zhang J, Jiang R, Liu L, Watkins T, Zhang F, Dong J-F. Traumatic brain injury-associated coagulopathy. J Neurotrauma. 2012;29(17):2597–605.
pubmed: 23020190
pmcid: 3510447
Harhangi BS, Kompanje EJO, Leebeek FWG, Maas AIR. Coagulation disorders after traumatic brain injury. Acta Neurochir (Wien). 2008;150(2):165–75.
Engström M, Romner B, Schalén W, Reinstrup P. Thrombocytopenia predicts progressive hemorrhage after head trauma. J Neurotrauma. 2005;22(2):291–6.
pubmed: 15716634
Allard CB, Scarpelini S, Rhind SG, Baker AJ, Shek PN, Tien H, et al. Abnormal coagulation tests are associated with progression of traumatic intracranial hemorrhage. J Trauma. 2009;67(5):959–67.
pubmed: 19901655
Hulka F, Mullins RJ, Frank EH. Blunt brain injury activates the coagulation process. Arch Surg. 1996;131(9):923–7 (discussion 927–8).
pubmed: 8790176
Kearney TJ, Bentt L, Grode M, Lee S, Hiatt JR, Shabot MM. Coagulopathy and catecholamines in severe head injury. J Trauma. 1992;32(5):608–11 (discussion 611–2).
pubmed: 1588649
Piek J, Chesnut RM, Marshall LF, van Berkum-Clark M, Klauber MR, Blunt BA, et al. Extracranial complications of severe head injury. J Neurosurg. 1992;77(6):901–7.
pubmed: 1432133
Laroche M, Kutcher ME, Huang MC, Cohen MJ, Manley GT. Coagulopathy after traumatic brain injury. Neurosurgery. 2012;70(6):1334–45.
pubmed: 22307074
Nakae R, Takayama Y, Kuwamoto K, Naoe Y, Sato H, Yokota H. Time course of coagulation and fibrinolytic parameters in patients with traumatic brain injury. J Neurotrauma. 2016;33(7):688–95.
pubmed: 26414158
McCully SP, Schreiber MA. Traumatic brain injury and its effect on coagulopathy. Semin Thromb Hemost. 2013;39(8):896–901.
pubmed: 24114009
Davis PK, Musunuru H, Walsh M, Cassady R, Yount R, Losiniecki A, et al. Platelet dysfunction is an early marker for traumatic brain injury-induced coagulopathy. Neurocrit Care. 2013;18(2):201–8.
pubmed: 22847397
Castellino FJ, Chapman MP, Donahue DL, Thomas S, Moore EE, Wohlauer MV, et al. Traumatic brain injury causes platelet adenosine diphosphate and arachidonic acid receptor inhibition independent of hemorrhagic shock in humans and rats. J Trauma Acute Care Surg. 2014;76(5):1169–76.
pubmed: 24747445
pmcid: 4065716
Foley JH, Conway EM. Cross talk pathways between coagulation and inflammation. Circ Res. 2016;118(9):1392–408.
pubmed: 27126649
Atefi G, Aisiku O, Shapiro N, Hauser C, Dalle Lucca J, Flaumenhaft R, et al. Complement activation in trauma patients alters platelet function. Shock. 2016;46(3 Suppl 1):83–8.
pubmed: 27355402
Cohen MJ, Brohi K, Ganter MT, Manley GT, Mackersie RC, Pittet J-F. Early coagulopathy after traumatic brain injury: the role of hypoperfusion and the protein C pathway. J Trauma. 2007;63(6):1254–61 (discussion 1261–2).
pubmed: 18212647
Hijazi N, Abu Fanne R, Abramovitch R, Yarovoi S, Higazi M, Abdeen S, et al. Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. Blood. 2015;125(16):2558–67.
pubmed: 25673638
pmcid: 4400292
Eddleston M, la Torre de JC, Oldstone MB, Loskutoff DJ, Edgington TS, Mackman N. Astrocytes are the primary source of tissue factor in the murine central nervous system. A role for astrocytes in cerebral hemostasis. J Clin Invest. 1993;92(1):349–58.
pubmed: 8326003
pmcid: 293611
Nekludov M, Mobarrez F, Gryth D, Bellander B-M, Wallen H. Formation of microparticles in the injured brain of patients with severe isolated traumatic brain injury. J Neurotrauma. 2014;31(23):1927–33.
pubmed: 24956150
Tian Y, Salsbery B, Wang M, Yuan H, Yang J, Zhao Z, et al. Brain-derived microparticles induce systemic coagulation in a murine model of traumatic brain injury. Blood. 2015;125(13):2151–9.
pubmed: 25628471
pmcid: 4375111
Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res. 2010;107(9):1047–57.
pubmed: 21030722
Morel O, Morel N, Jesel L, Freyssinet J-M, Toti F. Microparticles: a critical component in the nexus between inflammation, immunity, and thrombosis. Semin Immunopathol. 2011;33(5):469–86.
pubmed: 21866419
Mooberry MJ, Key NS. Microparticle analysis in disorders of hemostasis and thrombosis. Cytometry A. 2016;89(2):111–22.
pubmed: 25704723
Zhang D, Gong S, Jin H, Wang J, Sheng P, Zou W, et al. Coagulation parameters and risk of progressive hemorrhagic injury after traumatic brain injury: a systematic review and meta-analysis. Biomed Res Int. 2015;2015(6):261825-10.
Goodnight SH, Kenoyer G, Rapaport SI, Patch MJ, Lee JA, Kurze T. Defibrination after brain-tissue destruction: a serious complication of head injury. N Engl J Med. 1974;290(19):1043–7.
pubmed: 4821906
Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol. 2003;23(1):17–25.
pubmed: 12524220
Refaai MA, Riley P, Mardovina T, Bell PD. The Clinical Significance of Fibrin Monomers. Thromb Haemost. 2018;118(11):1856–66.
pubmed: 30312978
Rao A, Lin A, Hilliard C, Fu R, Lennox T, Barbosa R, et al. The utility of thromboelastography for predicting the risk of progression of intracranial hemorrhage in traumatic brain injury patients. Neurosurgery. 2017;64(CN_suppl_1):182–7.
pubmed: 28899039
pmcid: 6433435